Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

NCT01889277 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy

Interventions

DRUG: MT-3995-Low
DRUG: MT-3995-High
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation